title: Clinical investigation of neuraxially administered drugs: a regulatory perspective.
authors.forename: Lex W
authors.initials: LW
authors.lastname: Schultheis
authors.forename: Bindi M
authors.initials: BM
authors.lastname: Nikhar
authors.forename: R Daniel
authors.initials: RD
authors.lastname: Mellon
authors.forename: Suresh
authors.initials: S
authors.lastname: Doddapaneni
authors.forename: Danae D
authors.initials: DD
authors.lastname: Christodoulo
authors.forename: Rigoberto
authors.initials: R
authors.lastname: Roca
authors.forename: Bob A
authors.initials: BA
authors.lastname: Rappaport
mesh_terms: D000328:Adult; D015360:Analgesia, Epidural; D016362:Analgesia, Obstetrical; D000779:Anesthetics, Local; D002045:Bupivacaine; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D005260:Female; D006801:Humans; D007880:Legislation, Drug; D009388:Neostigmine / Q000008:administration & dosage* / Q000737:chemistry; D011247:Pregnancy; D014481:United States
chemical_list: D000779:Anesthetics, Local; D002800:Cholinesterase Inhibitors; D009388:Neostigmine; D002045:Bupivacaine